AR057247A1 - Composiciones que comprenden por lo menos una enzima para reducir el estres inmunologico - Google Patents

Composiciones que comprenden por lo menos una enzima para reducir el estres inmunologico

Info

Publication number
AR057247A1
AR057247A1 ARP060105545A ARP060105545A AR057247A1 AR 057247 A1 AR057247 A1 AR 057247A1 AR P060105545 A ARP060105545 A AR P060105545A AR P060105545 A ARP060105545 A AR P060105545A AR 057247 A1 AR057247 A1 AR 057247A1
Authority
AR
Argentina
Prior art keywords
compositions
animal
enzyme
reduce immune
immune stress
Prior art date
Application number
ARP060105545A
Other languages
English (en)
Original Assignee
Chemgen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemgen Corp filed Critical Chemgen Corp
Publication of AR057247A1 publication Critical patent/AR057247A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/189—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/244—Endo-1,3(4)-beta-glucanase (3.2.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C12N9/2494—Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01006—Endo-1,3(4)-beta-glucanase (3.2.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01014—Chitinase (3.2.1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01039—Glucan endo-1,3-beta-D-glucosidase (3.2.1.39)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01078—Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones adecuadas para su administracion por vía oral a un animal que comprenden al menos una enzima reductora del estrés inmunologico en una cantidad eficaz para disminuir el nivel de proteína de fase aguda positiva en dicho animal, incrementar el nivel de proteína de fase aguda negativa en dicho animal y/o mejorar el rendimiento del crecimiento del animal, asimismo se proveen métodos para utilizar dichas composiciones. Las composiciones incluyen composiciones de alimento para animales, composiciones líquidas distintas de un alimento para animales y composiciones solidas distintas de un alimento para animales.
ARP060105545A 2005-12-15 2006-12-15 Composiciones que comprenden por lo menos una enzima para reducir el estres inmunologico AR057247A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75033905P 2005-12-15 2005-12-15

Publications (1)

Publication Number Publication Date
AR057247A1 true AR057247A1 (es) 2007-11-21

Family

ID=38218427

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105545A AR057247A1 (es) 2005-12-15 2006-12-15 Composiciones que comprenden por lo menos una enzima para reducir el estres inmunologico

Country Status (35)

Country Link
US (5) US7914782B2 (es)
EP (2) EP1973561B1 (es)
JP (1) JP5189989B2 (es)
KR (2) KR101399205B1 (es)
CN (3) CN102293323A (es)
AR (1) AR057247A1 (es)
AT (1) ATE497779T1 (es)
AU (1) AU2006329927B2 (es)
BR (1) BRPI0620155B1 (es)
CA (1) CA2633066C (es)
CL (1) CL2011000941A1 (es)
CR (1) CR10116A (es)
DE (1) DE602006020074D1 (es)
DK (1) DK1973561T3 (es)
EC (1) ECSP088578A (es)
ES (1) ES2361819T3 (es)
GT (1) GT200600512A (es)
HN (1) HN2008000906A (es)
HR (1) HRP20080319B1 (es)
IL (2) IL192088A (es)
IN (1) IN2008DE06112A (es)
MX (1) MX284326B (es)
MY (1) MY145870A (es)
NO (1) NO340818B1 (es)
NZ (1) NZ569186A (es)
PE (1) PE20070840A1 (es)
PL (1) PL1973561T3 (es)
PT (1) PT1973561E (es)
RU (1) RU2465005C2 (es)
SI (1) SI1973561T1 (es)
SV (1) SV2008002942A (es)
TW (2) TWI402039B (es)
UA (1) UA95266C2 (es)
WO (1) WO2007075343A2 (es)
ZA (1) ZA200805780B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145870A (en) * 2005-12-15 2012-05-15 Lilly Co Eli Enzymes for reduced immunological stress
EA029906B1 (ru) * 2012-02-16 2018-05-31 Эланко Юэс Инк. Способы и композиции для уменьшения воздействия отходов животноводства на окружающую среду
US20160183561A1 (en) * 2013-07-26 2016-06-30 Novozymes A/S Polypeptides having a-L-Galactosidase Activity and Polynucleotides Encoding Same
DK3119901T3 (da) * 2014-03-21 2021-07-26 Dsm Ip Assets Bv Fremgangsmåde til behanlding af gærcellevægge med en laminaripentaose-producerende beta-1,3-glucanase
CN106771257A (zh) * 2017-01-24 2017-05-31 北京美正生物科技有限公司 一种检测血清淀粉样蛋白a的酶联免疫吸附试剂盒及其制备方法和用途
CN107156522A (zh) * 2017-06-23 2017-09-15 都匀市山郎科技养殖有限公司 一种鸡饲料
BE1030865B1 (nl) * 2022-09-12 2024-04-09 Nu3Guts Bv Voederadditief voor het verbeteren van de darmgezondheid en/of de verteerbaarheid van voeder in vee

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201949A (ja) * 1982-05-17 1983-11-25 Kyodo Shiryo Kk 家畜用配合飼料
US5372939A (en) * 1991-03-21 1994-12-13 The United States Of America As Represented By The United States Department Of Energy Combined enzyme mediated fermentation of cellulous and xylose to ethanol by Schizosaccharoyces pombe, cellulase, β-glucosidase, and xylose isomerase
JP2942384B2 (ja) * 1991-06-07 1999-08-30 株式会社ヤクルト本社 飼料効率改善添加剤
GB2261877A (en) 1991-11-21 1993-06-02 Kyowa Hakko Kogyo Kk Animal feed additive comprising enzyme and amino acid
AU4835693A (en) * 1993-08-13 1995-03-14 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
US5861271A (en) * 1993-12-17 1999-01-19 Fowler; Timothy Cellulase enzymes and systems for their expressions
EP1142485B1 (en) * 1994-04-22 2008-02-27 Novozymes A/S A method for improving the solubility of vegetable proteins
GB9416841D0 (en) * 1994-08-19 1994-10-12 Finnfeeds Int Ltd An enzyme feed additive and animal feed including it
NL1003096C2 (nl) * 1995-05-15 1996-11-19 Gist Brocades Bv Application of phospholipases in animal feed.
JP2001057852A (ja) * 1995-06-14 2001-03-06 Showa Denko Kk 耐熱酵素含有飼料用組成物
US5807694A (en) * 1995-09-07 1998-09-15 Economic Innovation And Technology Council, University Of Manitoba Detection of salmonella enteritidis and other pathogenic microorganisms and monoclonal antibody useful therefor
DE69621146T2 (de) * 1995-11-06 2002-11-28 Novozymes A/S, Bagsvaerd Verwendung von Galactanase in Tierfutter
WO1997039114A1 (en) * 1996-04-12 1997-10-23 Novo Nordisk A/S AN ENZYME WITH β-1,3-GLUCANASE ACTIVITY
CN1092495C (zh) 1996-05-03 2002-10-16 开姆根有限公司 半纤维素酶在低热焓饲料中的应用
US6162473A (en) * 1996-05-03 2000-12-19 Chemgen Corporation Hemicellulase use in feeds with low caloric content
US20020164751A1 (en) * 1996-06-19 2002-11-07 Short Jay M. Enzymes having thermostable phosphatase activity and methods of use thereof
GB9623539D0 (en) 1996-11-12 1997-01-08 Biotal Ltd Enzymes and their use
GB2327345B (en) 1997-07-18 1999-06-23 Finnfeeds Int Ltd Use of an enzyme for manufacturing an agent for controlling bacterial infection
US6022566A (en) * 1997-12-02 2000-02-08 Balchem Corporation Method for increasing the feed intake, feed efficiency, daily gain and/or carcass grade in ruminants
EP0976838A1 (en) * 1998-05-06 2000-02-02 Rhone-Poulenc Nutrition Animale Enzymes mixture
US6331426B1 (en) * 1999-02-11 2001-12-18 Novozymes A/S Bacterial galactanases and use thereof
US6213930B1 (en) * 1999-03-15 2001-04-10 Wisconsin Alumni Research Foundation Method of using anti-phospholipase A2 antibodies to enhance growth or improve feed efficiency
US6500658B1 (en) * 1999-08-17 2002-12-31 Novozymes, A/S Xyloglucanase from Malbranchea
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
GB0010748D0 (en) 2000-05-05 2000-06-28 Brown Paul D Tricep exercise horse (fold up and portable)
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
GB2371013B (en) 2001-01-16 2004-06-09 Terry John Claydon Copying apparatus
IL157006A0 (en) * 2001-01-17 2004-02-08 Univ Ramot Chitinases, derived from carnivorous plants, polynucleotide sequence encoding thereof, and methods of isolating and using same
DE10105306A1 (de) * 2001-02-02 2002-08-22 Nutrinova Gmbh Futtermittel für die Nutztieraufzucht enthaltend Sorbinsäure und Enzyme
DE10105347A1 (de) * 2001-02-05 2002-08-22 Nutrinova Gmbh Sorbinsäurepräparat enthaltend Probiotika als Futtermittelzusatz in der Nutztieraufzucht
IE20011100A1 (en) * 2001-12-21 2003-07-09 Vsl Pharma Ltd Analytical Method for Detecting Alkaline Sphingomyelinase and Kit for Use in Such Method
AU2003203142A1 (en) * 2002-01-25 2003-09-02 Dsm Ip Assets B.V. Thermostable enzyme compositions
AU2003304239A1 (en) * 2002-11-13 2005-01-13 Yvonne J. Rosenberg A pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger
AU2003298036A1 (en) 2002-12-12 2004-07-09 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
US20110142817A1 (en) * 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
AU2005210581B2 (en) 2004-02-04 2010-06-24 Am-Pharma B.V. Use of alkaline phosphatase for the detoxification of LPS present at mucosal barriers
EP1740204B1 (en) * 2004-04-01 2018-03-14 Chiesi Farmaceutici S.p.A. Medicinal use of alpha-mannosidase
EP1869200B1 (en) * 2005-03-25 2008-09-03 Universiteit Gent Enzymatic demethylation of flavonoids
CN1699576A (zh) * 2005-06-30 2005-11-23 江南大学 一种内切β－1,3葡聚糖酶基因及其克隆方法
WO2007032818A2 (en) * 2005-09-12 2007-03-22 Zoltan Laboratories Llc Compounds and compositions to control abnormal cell growth
MY145870A (en) * 2005-12-15 2012-05-15 Lilly Co Eli Enzymes for reduced immunological stress
ES2421717T3 (es) * 2008-02-29 2013-09-05 Alloksys Life Science B V Fosfatasa alcalina para aumentar la actividad del sistema inmune en un mamífero con riesgo de enfermedades inflamatorias

Also Published As

Publication number Publication date
US8778648B2 (en) 2014-07-15
NO20083035L (no) 2008-09-11
IN2008DE06112A (es) 2008-09-26
EP2263685A2 (en) 2010-12-22
SV2008002942A (es) 2008-12-03
WO2007075343A2 (en) 2007-07-05
IL192088A0 (en) 2009-02-11
HRP20080319B1 (hr) 2015-11-20
KR20080081972A (ko) 2008-09-10
EP1973561A2 (en) 2008-10-01
US20110171344A1 (en) 2011-07-14
TW201336425A (zh) 2013-09-16
MY145870A (en) 2012-05-15
ATE497779T1 (de) 2011-02-15
RU2008128583A (ru) 2010-01-20
CN102293323A (zh) 2011-12-28
MX2008007735A (en) 2008-08-27
IL192088A (en) 2013-07-31
BRPI0620155A2 (pt) 2011-11-01
KR101454032B1 (ko) 2014-10-27
KR20130082514A (ko) 2013-07-19
HRP20080319A2 (en) 2008-12-31
NO340818B1 (no) 2017-06-26
DK1973561T3 (da) 2011-05-23
JP2009519712A (ja) 2009-05-21
AU2006329927A1 (en) 2007-07-05
DE602006020074D1 (de) 2011-03-24
CA2633066C (en) 2015-01-20
EP1973561B1 (en) 2011-02-09
US20070141041A1 (en) 2007-06-21
PT1973561E (pt) 2011-05-12
CN101374544A (zh) 2009-02-25
IL227318A (en) 2016-11-30
CN101374544B (zh) 2016-05-18
US20110177195A1 (en) 2011-07-21
PE20070840A1 (es) 2007-08-25
US20170156371A1 (en) 2017-06-08
CN105831428B (zh) 2020-12-01
UA95266C2 (uk) 2011-07-25
BRPI0620155B1 (pt) 2015-07-21
NZ569186A (en) 2011-09-30
US20110171345A1 (en) 2011-07-14
ZA200805780B (en) 2009-03-25
TW200731932A (en) 2007-09-01
HN2008000906A (es) 2011-07-12
EP2263685A3 (en) 2011-04-06
PL1973561T3 (pl) 2011-08-31
CA2633066A1 (en) 2007-07-05
KR101399205B1 (ko) 2014-05-27
US7914782B2 (en) 2011-03-29
TWI402039B (zh) 2013-07-21
ES2361819T3 (es) 2011-06-22
WO2007075343A3 (en) 2007-10-04
SI1973561T1 (sl) 2011-07-29
ECSP088578A (es) 2008-10-31
AU2006329927B2 (en) 2011-09-29
CR10116A (es) 2008-10-28
CL2011000941A1 (es) 2014-08-08
CN105831428A (zh) 2016-08-10
JP5189989B2 (ja) 2013-04-24
MX284326B (en) 2011-03-01
TWI619506B (zh) 2018-04-01
GT200600512A (es) 2007-06-28
RU2465005C2 (ru) 2012-10-27

Similar Documents

Publication Publication Date Title
AR057247A1 (es) Composiciones que comprenden por lo menos una enzima para reducir el estres inmunologico
AR106702A2 (es) Uso de un anticuerpo antagonista anti-ngf para la preparación de un medicamento
ECSP088618A (es) Composiciones y métodos de uso para anticuerpos de dickkopf-1 y/o -4
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
CL2012003656A1 (es) Uso de una composicion que comprende una enzima de reemplazo para la enzima lisosomal a una concentracion mayor a 5 mg/ml para tratar sintomas somaticos de la deficiencia de la enzima subyacente.
ES2572160T3 (es) Una nueva preparación farmacéutica para preeclampsia
AR087745A1 (es) Composiciones y metodos que comprenden una variante de enzima lipolitica
CL2009001476A1 (es) Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular.
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
UY29708A1 (es) Metodos y aparatos para la reducción del contenido de proteina en extendedores de celulas de esperma
CL2011002761A1 (es) Compuestos derivados de heterociclos sustituidos, inhibidores del canal romk; composición farmacéutica; y su uso para provocar diuresis, natriuresis o ambas, hipertension, insuficiencia cardiaca, insuficiencia renal aguda y crónica y síndrome nefrótico, entre otras enfermedades.
EA200700965A1 (ru) Трегалоза и/или изомальтулоза в качестве носителя для сухой ароматической композиции
CO6331366A2 (es) Composiciones liquidas de limpieza para la remocion de grasa
WO2006073890A3 (en) Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
BR112014014834A2 (pt) composições para cuidado oral
ECSP10010716A (es) Combinaciones farmaceuticas.
CY1115938T1 (el) Νεα συνθεση για αυξηση της bio-διαθεσιμοτητας της νεουρτουρινης (neurturin)
EA201071371A1 (ru) Упаковка для биологического материала
ATE541855T1 (de) Weitere kristalline formen von rostafuroxin
AR058621A1 (es) Metodods para reducir la proteina c reactiva
DK1537204T3 (da) Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller
ATE442055T1 (de) Fischfutter mit sojaprotein

Legal Events

Date Code Title Description
FG Grant, registration